Association of Plasma Human Immunodeficiency Virus Type 1 RNA Level With Risk of Clinical Progression in Patients With Advanced Infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups

J Infect Dis. 1996 Oct;174(4):704-12. doi: 10.1093/infdis/174.4.704.

Abstract

Human immunodeficiency virus (HIV)-1 RNA level in plasma was evaluated as a surrogate marker for disease progression in a clinical trial of advanced HIV-1 infection. Baseline HIV-1 RNA level was an independent predictor of disease progression (relative hazard [RH] for each doubling of HIV-1 RNA level, 1.26; 95% confidence interval [CI], 1.03-1.54; P = .02), after adjusting for the week 4 change in HIV-1 RNA level, baseline CD4 cell count, syncytium-inducing phenotype, clinical status at study entry, and therapy randomization. A 50% reduction in HIV-1 RNA level was associated with a 27% decrease in the adjusted risk of disease progression during the study (RH, 0.73; 95% CI, 0.52-1.02; P = .07). The partial validation of HIV-1 RNA as a predictor for clinical end points has implications for the use of HIV-1 RNA in clinical trials and practice.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy
  • Acquired Immunodeficiency Syndrome / virology*
  • Adult
  • CD4 Lymphocyte Count
  • Female
  • HIV-1 / genetics*
  • Humans
  • Male
  • Polymerase Chain Reaction
  • RNA, Viral / blood*
  • Risk
  • Zidovudine / therapeutic use

Substances

  • RNA, Viral
  • Zidovudine